Abstract:Vorinostat (SAHA) with great therapeutic potential has been approved by the FDA for the treatment of cutaneous T-cell lymphoma as the first HDACs inhibitor, but the drawbacks associated with hydroxamic acid group (poor stability, easy metabolism, weak binding ability to class IIa isozymes, and poor selectivity) have been exposed during the continuous clinical application. Based on the pharmacophore of HDAC inhibitors, two series of compounds with novel zinc binding group (ZBG) were designed and synthesized, and the antitumor bioactivities were evaluated in four human cancer cell lines (A549, Hela, HepG2, and MCF-7). Among the synthesized compounds, compounds a6, a9, a10, b8, and b9 exhibited promising inhibitory activities against the selected tumor cell lines, especially compounds a9 and b8 on Hela's cytostatic activity (a9: IC50 = 11.15 +/- 3.24 mu M; b8: IC50 = 13.68 +/- 1.31 mu M). The enzyme inhibition assay against Hela extracts and HDAC1&6 subtypes showed that compound a9 had a certain broad-spectrum inhibitory activity, while compound b8 had selective inhibitory activity against HDAC6, which was consistent with Western blot results. In addition, the inhibitory mechanism of compounds a9 and b8 in HDAC1&6 were both compared through computational approaches, and the binding interactions between the compounds and the enzymes target were analyzed from the perspective of energy profile and conformation. In summary, the compounds with novel ZBG exhibited certain antitumor activities, providing valuable hints for the discovery of novel HDAC inhibitors.

Synthesis and biological evaluation of largazole zinc-binding group analogs

Biological Evaluation of New Largazole Analogues: Alteration of Macrocyclic Scaffold with Click Chemistry

Synthetic Routes And Biological Evaluation Of Largazole And Its Analogues As Potent Histone Deacetylase Inhibitors

Total syntheses of the histone deacetylase inhibitors largazole and 2-epi-largazole: application of N-heterocyclic carbene mediated acylations in complex molecule synthesis.

Synthesis and Biological Evaluation of HDAC Inhibitors With a Novel Zinc Binding Group.

Design, synthesis and biological evaluation of novel HDAC inhibitors: sulphur-containing zinc binding groups

Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships

Total Synthesis and Biological Evaluation of Largazole and Derivatives with Promising Selectivity for Cancers Cells.

Design, Synthesis and Bioactivity Evaluations of 8-Substituted-quinoline-2-carboxamide Derivatives As Novel Histone Deacetylase (HDAC) Inhibitors.

Targeting the Zinc-Dependent Histone Deacetylases (HDACs) for Drug Discovery

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

[Design, Synthesis, and Biological Activities of Histone Deacetylase Inhibitors with Diketo Ester As Zinc Binding Group].

Design, Synthesis and Biological Evaluation of Isoquinoline-Based Derivatives As Novel Histone Deacetylase Inhibitors

Synthesis and Structure‐activity Relationship of Thiol‐based Histone Deacetylase 6 Inhibitors

Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study

Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.

Computational Exploration of Zinc Binding Groups for Hdac Inhibition

Synthesis and Biological Evaluation of a New Series of Histone Deacetylases Inhibitors

Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue

Design and Synthesis of HDAC Inhibitors to Enhance the Therapeutic Effect of Diffuse Large B-cell Lymphoma by Improving Metabolic Stability and Pharmacokinetic Characteristics.

Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives As HDAC6 Isoform-Selective Inhibitors.